[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651397":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":41,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":75,"whyStopped":20,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Incretin treatment combined with unilateral resistance training","EXPERIMENTAL","Participants will initiate incretin-based receptor agonist treatment as part of routine clinical care. The study intervention consists of supervised unilateral resistance training performed twice weekly for 13 weeks. No incretin-based medication is assigned or administered by the study.",[13],"Behavioral: Unilateral Resistance Training",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","Unilateral Resistance Training","Supervised resistance training of one leg, two sessions per week for 13 weeks, during incretin-based receptor agonist treatment. The trained leg will be randomly assigned, and the contralateral leg will serve as an internal within-participant control.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Eric B Emanuelsson, PhD","CONTACT","+46730266626","eric.emanuelsson@ki.se",[28],{"facility":5,"status":20,"city":29,"state":20,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Stockholm","17177","Sweden","SE",{"type":34,"coordinates":35},"Point",[36,37],18.06871,59.32938,{"lat":37,"lon":36},[40],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Eric Emanuelsson","Postdoctoral Researcher",[46],{"name":47,"class":48},"Region Stockholm","OTHER_GOV","100651397","preserving-muscle-mass-during-incretin-induced-weight-loss-100651397",false,"NCT07761923","Preserving Muscle Mass During Incretin-Induced Weight Loss","Resistance Exercise Training to Preserve Muscle Mass and Physical Function During Incretin-Based Weight Loss","INCRETraIN","Inclusion Criteria:\n\n* Adults aged 18-64 years with obesity.\n* Planned initiation of incretin-based obesity pharmacotherapy as part of routine clinical care.\n* Able to participate in supervised unilateral resistance training.\n* Able to complete physical function tests.\n* Able to attend study visits at the study center.\n* Able to provide written informed consent in the Swedish language.\n\nExclusion Criteria:\n\n* Contraindication to magnetic resonance imaging.\n* Medical condition preventing resistance training or physical function testing.\n* Medical condition preventing skeletal muscle or adipose tissue biopsy.\n* Inability to understand study information in Swedish or provide informed consent.","ALL","18 Years","64 Years",{"count":61,"type":62},20,"ESTIMATED","INTERVENTIONAL",[65],"NA","Treatment with appetite suppressant drugs, including incretin-based receptor agonists, generally leads to clinically meaningful weight loss and reduced cardiometabolic risk. However, weight loss may include not only loss of adipose tissue but also loss of skeletal muscle mass, which ultimately may impair physical function and metabolic health.\n\nResistance training is an effective strategy to maintain or increase skeletal muscle mass during weight loss, but its effects during treatment with appetite suppressant obesity medications have been studied insufficiently. This study will investigate whether unilateral resistance training during incretin-based receptor agonist treatment can preserve or improve skeletal muscle mass. Additionally, the study will determine whether preservation of muscle is accompanied by the preservation of muscle function and\u002For molecular adaptations in skeletal muscle, adipose tissue and blood.\n\nParticipants will be adults with obesity who are about to start treatment with an incretin-based receptor agonist as part of routine clinical care. During the 13-week intervention, participants will perform supervised unilateral resistance training two times per week, training one leg while the other leg serves as an internal control. Data and tissue collection will take place before treatment start and after 13 weeks. Assessments include whole-body magnetic resonance imaging, blood sampling, skeletal muscle and adipose tissue biopsies, physical function tests, questionnaires, and monitoring of physical activity.",[68],"Obesity (BMI > 35)",[70,71,72,73,74],"Obesity","Incretins","Skeletal muscle","Resistance training","Exercise training","NOT_YET_RECRUITING","2026-08-10",{"date":78,"type":79},"2026-08-12","ACTUAL",{"date":81,"type":62},"2026-09-01",{"date":83,"type":62},"2029-01-01",{"name":5,"class":6},1]